ArticleJournal, genetic engineering & biotechnology2026
Bioinformatics-Guided structural characterization and immunogenicity assessment of multi-epitope vaccine candidates against Zika virus.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Zika virus (ZIKV) causes a significant global health threat, necessitating the development of effective vaccines. In this study, using bioinformatics and software-based vaccinology approaches, firstly we evaluated the antigenicity of all proteins of ZIKV (EU545988.1), identifying Protein Pr, E, and NS1 as the most antigenic. Subsequent investigation into the antigenic profiles of these proteins across the top 10 infectious ZIKV strains unveiled Strain Zika (USA, KU312312), Rio-U1 (Brazil, KX601166), and Zika (Brazil, KU321639) as harboring the highest antigenicity for Protein Pr (0.7194555), E (0.6559635), and NS1 (0.6115945), respectively. Next, T cell and B cell epitopes were predicted for these proteins, and their antigenicity, allergenicity, and toxicity were evaluated. Binding affinity of T cell epitopes with MHC I and II molecules was determined. Population coverage and conservancy analysis were conducted. Three B cell epitopes (ATMSYECPMLDHVQI, TMSGKAISFATTLG, and KDAHAKRQTVYVCKR) and three T cell epitopes (DLGHTCDATMSYECP, ALGGVMIFLSTAVSA, and TSVWLKYHPDSPRRL) from Protein Pr, E, and NS1 were identified as optimal vaccine candidates. Among them, ALGGVMIFLSTAVSA and TSVWLKYHPDSPRRL showed 100% conservancy and 71.88% and 95.24% Population coverage (worldwide) where DLGHTCDATMSYECP showed 95.24% Conservancy and 94.77% Population coverage. Using them, the multi-epitope vaccine (MEV) was constructed with an appropriate adjuvant (P29459) and linkers, including a His-tag for ease of isolation during in vivo procedures. Secondary and tertiary structures of the MEV were predicted, and physiochemical properties and subcellular localization were analyzed. Furthermore, allergenicity, toxicity and immune simulation of the MEV were assessed. Molecular docking analysis confirmed binding affinity with human receptor proteins TLR3 (PDB: 7C76) and stability was evaluated through Molecular Dynamics Simulation analysis. Post-translational modifications analysis was conducted, and in silico cloning in E. coli was performed to assess cloning feasibility of the MEV. This integrative approach provides insights into the development of a potential ZIKV vaccine, laying the groundwork for further wet lab validation and preclinical and clinical investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.